John McCalley

John McCalley inquired about the progress and remaining opportunity for AMDS account penetration in 2026 and beyond, and sought reaction to the impressive NEXUS data from STS, framing its market opportunity, competitive landscape, and potential for market expansion.

Answer

CEO Pat Mackin stated that AMDS is still in its 'first inning,' with 2025 focused on opening accounts and only penetrating about 10% of target accounts, expressing bullishness for 2026 growth. For NEXUS, Pat Mackin highlighted it as a nascent market with one approved competitor, emphasizing its platform technology for high-risk patients and its potential to expand the $150 million U.S. market, expecting PMA approval in H2.

John McCalley with Stifel inquired about the progress of AMDS account penetration and implant growth, and sought Artivion's reaction to the impressive NEXUS data from STS, including framing the market opportunity, competitive landscape, and potential for market expansion.

Answer

Pat Mackin, CEO, described AMDS as being in the 'first inning,' with only about 10% of target accounts opened in 2025, highlighting significant opportunity in 2026 for both new account openings and increased implants in existing accounts. Regarding NEXUS, he noted the nascent market for high-risk patients, the $150 million US market opportunity, and expressed confidence in NEXUS's competitive positioning and its role in Artivion's commitment to aortic technologies.